Clare F. Malone

Clare F. Malone

Auto-generated profile, based on publicly available information

Clare F. Malone

InduPro, Cambridge, USA

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 May 2024 in Science Advances
Verified
Journal Article
Open access
CMClare F. Malone
Clare F. Malone
NMNathaniel W. Mabe
Nathaniel W. Mabe
AFAlexandra B. Forman
Alexandra B. Forman
GAGabriela Alexe
Gabriela Alexe
KEKathleen L. Engel
Kathleen L. Engel
KSKimberly Stegmaier
Kimberly Stegmaier
Pediatric cancers are frequently driven by genomic alterations that result in aberrant transcription factor activity. Here, we used functional genomic screens to identify multiple genes within the transcriptional coactivator Spt-Ada-Gcn5-acetyltransferase (SAGA) complex as selective dependencies for MYCN -amplified neuroblastoma, a disease of dysregulated development driven by an aberrant oncogenic transcriptional program. We characterized the DNA recruitment sites of the SAGA complex in neuroblastoma and the consequences of loss of SAGA complex lysine acetyltransferase (KAT) activity on histone acetylation and gene expression. We demonstrate that loss of SAGA complex KAT activity is associated with reduced MYCN binding on chromatin, suppression of MYC/MYCN gene expression programs, and impaired cell cycle progression. Further, we showed that the SAGA complex is pharmacologically targetable in vitro and in vivo with a KAT2A/KAT2B proteolysis targeting chimeric. Our findings expand our understanding of the histone-modifying complexes that maintain the oncogenic transcriptional state in this disease and suggest therapeutic potential for inhibitors of SAGA KAT activity in MYCN -amplified neuroblastoma.

17 November 2022 in Cancer Research
Verified
Journal Article
Closed access
PDF file
CMClare F. Malone
Clare F. Malone
MKMinjee Kim
Minjee Kim
GAGabriela Alexe
Gabriela Alexe
KEKathleen Engel
Kathleen Engel
AFAlexandra B. Forman
Alexandra B. Forman
KSKimberly Stegmaier
Kimberly Stegmaier
Aberrant RAS/MAPK signaling is a common driver of oncogenesis that can be therapeutically targeted with clinically approved MEK inhibitors. Disease progression on single-agent MEK inhibitors is common, however, and combination therapies are typically required to achieve significant clinical benefit in advanced cancers. Here we focused on identifying MEK inhibitor-based combination therapies in neuroblastoma with mutations that activate the RAS/MAPK signaling pathway, which are rare at diagnosis but frequent in relapsed neuroblastoma. A genome-scale CRISPR-Cas9 functional genomic screen was deployed to identify genes that when knocked out sensitize RAS-mutant neuroblastoma to MEK inhibition. Loss of either CCNC or CDK8, two members of the mediator kinase module, sensitized neuroblastoma to MEK inhibition. Furthermore, small-molecule kinase inhibitors of CDK8 improved response to MEK inhibitors in vitro and in vivo in RAS-mutant neuroblastoma and other adult solid tumors. Transcriptional profiling revealed that loss of CDK8 or CCNC antagonized the transcriptional signature induced by MEK inhibition. When combined, loss of CDK8 or CCNC prevented the compensatory upregulation of progrowth gene expression induced by MEK inhibition. These findings propose a new therapeutic combination for RAS-mutant neuroblastoma and may have clinical relevance for other RAS-driven malignancies. Significance: Transcriptional adaptation to MEK inhibition is mediated by CDK8 and can be blocked by the addition of CDK8 inhibitors to improve response to MEK inhibitors in RAS-mutant neuroblastoma, a clinically challenging disease.

14 July 2026 in Cancer Discovery
Verified
Journal Article
Open access
SZSusu Zhang
Susu Zhang
KEKathleen L. Engel
Kathleen L. Engel
AFAssil Fahs
Assil Fahs
AJAra Jo
Ara Jo
CMClare F. Malone
Clare F. Malone
KSKimberly Stegmaier
Kimberly Stegmaier
Alveolar rhabdomyosarcoma (aRMS) is a fusion-driven pediatric cancer with poor survival and limited therapeutic options. To uncover novel vulnerabilities, we used complex-Map functional genomic data, identifying CDK8 as a dependency in aRMS. Both CDK8 knockout and pharmacologic inhibition impaired tumor cell growth and induced myogenic differentiation in vitro and in vivo. Compared with genetic loss, CDK8 pharmacologic inhibition induced more dynamic transcriptional changes. With a genome-scale CRISPR–Cas9 drug modifier screen, we determined that the maximal antitumor activity of the CDK8 inhibitor requires the presence of the Mediator kinase module, including CDK8, and transcriptional cooperation with the SAGA complex. We further identified SIX4 as a key transcription factor mediating CDK8 inhibitor–induced transcriptional activation of myogenic differentiation genes and impaired tumor proliferation. These findings suggest a distinct gain-of-function mechanism of the CDK8 inhibitor and establish a strong rationale for CDK8 inhibition as a differentiation-inducing therapeutic strategy in aRMS. Significance: We provide a framework for uncovering therapeutic targets by network-based analysis of functional genomic screens. We identify CDK8 as a druggable target in aRMS and determine that CDK8 inhibition drives myogenic differentiation and impairs tumor progression via a collaborative mechanism involving the Mediator kinase module, SAGA complex, and SIX4. See related commentary by Stevens and Hatley, p. 2210

9 September 2026 in Nature
Verified
Journal Article
Open access
PDF file
CSCody Scandore
Cody Scandore
CMClare F. Malone
Clare F. Malone
CMChristopher K. May
Christopher K. May
ARAnna K. de Regt
Anna K. de Regt
JGJeff Guernsey
Jeff Guernsey
OFOlugbeminiyi O. Fadeyi
Olugbeminiyi O. Fadeyi
The spatial organization of membrane proteins is an underexplored dimension of cell surface biology1,2. Spatial proximity shapes cellular function and therapeutic targetability2,3, yet efforts to identify tumour-associated antigens (TAAs) have largely focused on expression alone4. Here, we developed an industrialized surface protein proximity-mapping workflow to interrogate TAAs within their membrane microenvironments. Using this workflow, we generated 248 proximity maps across 12 receptor tyrosine kinases and 28 tumour cell systems. The resulting atlas enabled the development of MetaMap, a correlation-based analytical framework that defines spatial protein communities and infers conserved proximity relationships among non-targeted proteins, and establishes the concept of tumour-associated proximity antigens (TAPAs), a class of co-targets defined by disease-specific spatial proximity to TAAs rather than expression alone. Integrating these proximity-derived relationships within a multimodal prioritization framework, we identified and validated EGFR–CDCP1 as a TAA–TAPA pair that enhances tumour cell killing across therapeutic modalities. Together, this work advances disease-associated membrane proximity as a guiding principle for the design of precision multispecific therapeutics.

3 April 2023
Verified
Other
Open access
SOSarah Naomi Olsen
Sarah Naomi Olsen
AWAnia Wronski
Ania Wronski
ZCZafira Castaño
Zafira Castaño
BDBenjamin Dake
Benjamin Dake
CMClare Malone
Clare Malone
KCKaren Cichowski
Karen Cichowski

3 April 2023
Verified
Other
Open access
SOSarah Naomi Olsen
Sarah Naomi Olsen
AWAnia Wronski
Ania Wronski
ZCZafira Castaño
Zafira Castaño
BDBenjamin Dake
Benjamin Dake
CMClare Malone
Clare Malone
KCKaren Cichowski
Karen Cichowski
DAB2IP Expression in a Panel of MMTVNeu/RASAL2-/- Tumors.